Diabetic kidney disease (DKD) is a major microvascular complication of type 2 diabetes and a leading cause of end-stage kidney disease (ESKD). A reduction in urinary albumin of at least 30% is considered clinically meaningful to slow progression toward ESKD. Remote ischemic conditioning (RIC) — brief, repeated episodes of ischemia and reperfusion applied remotely (typically to a limb) — has been proposed to confer organ protection in a variety of settings. The RICADIME trial sought to determine whether RIC could reduce albuminuria in adults with type 2 diabetes and moderate to severely increased albumin excretion.
This study was a parallel-group, double-blind, sham-controlled, randomized clinical trial. A total of 40 normotensive adults with type 2 diabetes and moderate or severely increased albuminuria were enrolled and randomized in a 1:1 ratio to receive either active RIC (n = 20) or a sham procedure (n = 20) once weekly for 8 weeks. The abstract reports that participants were normotensive and had elevated albuminuria; additional baseline demographic and clinical characteristics were not detailed in the abstract.
Participants assigned to the active arm received weekly RIC for 8 weeks, while the control group received a sham procedure. The abstract confirms a double-blind design but does not describe the precise RIC protocol (for example, cuff inflation pressures, number and duration of ischemia-reperfusion cycles, or limb used) nor the details of the sham procedure. These protocol parameters were not reported in the abstract.
The predefined primary outcome was the reduction in urinary albumin at the end of 8 weeks. Secondary outcomes included changes in serum creatinine, estimated glomerular filtration rate (eGFR), and HbA1c. Safety and tolerability were monitored; the abstract reports adverse events in brief.
At 8 weeks, the RIC group experienced a median reduction in albuminuria of 37.9% (IQR: -7.5, 43.9). By contrast, the sham group had a median change representing a 1.10% increase in albuminuria (IQR: -5.6, 15.2). The between-group comparison for the primary outcome reached statistical significance (P = 0.015), indicating greater albuminuria reduction with RIC.
Serum creatinine decreased in the RIC arm from 1.00 mg/dL to 0.83 mg/dL, whereas it increased in the sham arm from 0.97 mg/dL to 1.10 mg/dL. This difference was statistically significant (P = 0.0004).
Mean eGFR improved in the RIC group from 85 to 99 mL/min/1.73 m2 (reported P = 0.0001). No significant change in HbA1c was detected between groups over the 8-week period.
These results indicate that weekly RIC for 8 weeks was associated with clinically and statistically significant reductions in albuminuria as well as improvements in serum creatinine and eGFR in this cohort.
Mild pain was reported as an adverse effect in 10% of participants in the RIC group. No adverse effects were reported in the sham group according to the abstract. The abstract does not report other safety outcomes, events of severe concern, or longer-term tolerability data.
Among adults with DKD enrolled in this randomized, double-blind, sham-controlled trial, treatment with weekly RIC for 8 weeks significantly reduced albuminuria and serum creatinine while improving eGFR. Glycated hemoglobin (HbA1c) did not change significantly over the study period. The trial is registered (CTRI/2024/09/074453) and was published in Postgraduate Medical Journal (2026).
The abstract provides clear primary and secondary outcomes and summary results but omits several details that are relevant for interpretation and application: the full RIC protocol parameters (cuff pressure, cycle durations, limb used), comprehensive baseline participant characteristics, concomitant medications (including renin‑angiotensin system inhibitors or SGLT2 inhibitors), randomization method and allocation concealment details, statistical analysis plan, and longer-term follow-up beyond 8 weeks. Safety reporting is limited in the abstract. Because these elements were not reported in the abstract, they cannot be summarized here and should be sought in the full text for clinical appraisal.
Note: All data and findings summarized here are taken from the PubMed abstract for the RICADIME randomized clinical trial (PMID: 42095727).